[A clinical trial Furlutal in the prevention of anorexia, weight loss and myelosuppression due to chemotherapy].
From October, 1993 to September, 1994 a controlled clinical trial was conducted in 60 patients on Furlutal in the prevention of anorexia, weight loss and myelosuppression caused by chemotherapy. Patients were randomly divieded into three groups, they received Furlutal in the 1st (group A), 2nd (group B) and every cycle in (group C), respectively. The results show that Furlutal is effective in preventing anorexia, weight loss and myelosuppression. In group A, 85% patients gained weight, averaged 2.5kg (range: 1-7kg); 80% in group B, averged 2.25kg (1-7kg) and 95% in group C, averaged 4kg (2.5-8kg). Grade III myelosuppression, according to WHO criteria, 52.5% occurred in of patients treated with 80 cycles of chemotherapy only while it occurred in 19% in those treated with 100 cycles of chemotherapy plus Furlutal (P < 0.01).
Wang
J
J
Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing.
Zhang
P
P
Wang
H
H
D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced / Q000517:prevention & control*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008875:Middle Aged; D015431:Weight Loss / Q000187:drug effects*
D008525:Medroxyprogesterone